Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials
- PMID: 32500209
- PMCID: PMC7351848
- DOI: 10.1007/s00213-020-05548-2
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials
Abstract
Rationale: Posttraumatic stress disorder (PTSD) is a chronic condition that has wide-ranging negative effects on an individual's health and interpersonal relationships. Treatments with long-term benefits are needed to promote the safety and well-being of those suffering from PTSD.
Objectives: To examine long-term change in PTSD symptoms and additional benefits/harms after 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment of PTSD.
Methods: Participants received two to three active doses of MDMA (75-125 mg) during blinded or open-label psychotherapy sessions with additional non-drug therapy sessions. PTSD symptoms were assessed using the Clinician-Administered PTSD Scale for DSM IV (CAPS-IV) at baseline, 1 to 2 months after the last active MDMA session (treatment exit), and at least 12 months post final MDMA session (LTFU). A mixed-effect repeated-measures (MMRM) analysis assessed changes in CAPS-IV total severity scores. The number of participants who met PTSD diagnostic criteria was summarized at each time point. Participants completed a long-term follow-up questionnaire.
Results: There was a significant reduction in CAPS-IV total severity scores from baseline to treatment exit (LS mean (SE) = - 44.8 (2.82), p < .0001), with a Cohen's d effect size of 1.58 (95% CI = 1.24, 1.91). CAPS-IV scores continued to decrease from treatment exit to LTFU (LS mean (SE) = - 5.2 (2.29), p < .05), with a Cohen's d effect size of 0.23 (95% CI = 0.04, 0.43). The number of participants who no longer met PTSD criteria increased from treatment exit (56.0%) to LTFU (67.0%). The majority of participants reported benefits, including improved relationships and well-being, and a minority reported harms from study participation.
Conclusions: PTSD symptoms were reduced 1 to 2 months after MDMA-assisted psychotherapy, and symptom improvement continued at least 12 months post-treatment. Phase 3 trials are investigating this novel treatment approach in a larger sample of participants with chronic PTSD.
Trial registration: clinicaltrials.gov Identifier: NCT00090064, NCT00353938, NCT01958593, NCT01211405, NCT01689740, NCT01793610.
Keywords: Long-term follow-up; MDMA; MDMA-assisted psychotherapy; PTSD.
Conflict of interest statement
Lisa Jerome, Allison Feduccia, and Julie Wang received salary support for full-time employment with MPBC. Scott Hamilton, Mt Tam Data Analysis, received salary support from MPBC as an independent biostatistician. Berra Yazar-Klosinski received salary support for full-time employment with MAPS. Amy Emerson received salary support for full-time employment with MPBC. Michael Mithoefer received salary support from MPBC as a clinical investigator and clinical trial medical monitor as well as for training and supervision of research psychotherapists. Rick Doblin received salary support for full-time employment with MAPS.
Similar articles
-
[MDMA-assisted therapy for PTSD].Laeknabladid. 2024 May;110(5):254-261. doi: 10.17992/lbl.2024.05.793. Laeknabladid. 2024. PMID: 38713560 Review. Icelandic.
-
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. Front Psychiatry. 2019. PMID: 31572236 Free PMC article. Review.
-
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. Psychopharmacology (Berl). 2019. PMID: 31065731 Free PMC article. Clinical Trial.
-
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.J Psychopharmacol. 2018 Dec;32(12):1295-1307. doi: 10.1177/0269881118806297. Epub 2018 Oct 29. J Psychopharmacol. 2018. PMID: 30371148 Free PMC article. Clinical Trial.
-
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1. Lancet Psychiatry. 2018. PMID: 29728331 Clinical Trial.
Cited by
-
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials. 2024 May 21;25(1):336. doi: 10.1186/s13063-024-08174-x. Trials. 2024. PMID: 38773523 Free PMC article.
-
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.Arch Toxicol. 2024 May 14. doi: 10.1007/s00204-024-03765-8. Online ahead of print. Arch Toxicol. 2024. PMID: 38743292 Review.
-
Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology. 2024 Jul;49(8):1208-1226. doi: 10.1038/s41386-024-01865-8. Epub 2024 Apr 23. Neuropsychopharmacology. 2024. PMID: 38654146 Free PMC article.
-
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147. Curr Neuropharmacol. 2024. PMID: 38284341 Free PMC article. Review.
-
Effects of MDMA-assisted therapy for PTSD on self-experience.PLoS One. 2024 Jan 10;19(1):e0295926. doi: 10.1371/journal.pone.0295926. eCollection 2024. PLoS One. 2024. PMID: 38198456 Free PMC article. Clinical Trial.
References
-
- Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway GP, Mendelson JE. Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016;30:378–387. - PubMed
-
- Barone W, Beck J, Mitsunaga-Whitten M, Perl P. Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. J Psychoactive Drugs. 2019;51:199–208. - PubMed
-
- Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom A. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ (Clinical research ed) 2017;358:j3927. - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous